Table 1.
Experimental design and group assignments for all three studies.
| Treatment group | Source of MDA | Challenge strain or vaccine typea | N | Indirect contacts (N) |
|---|---|---|---|---|
| Study 1 | ||||
| No MDA/NC | None | None | 9 | - |
| No MDA/H1N2 | None | H1N2-δ1(1:7)b | 10 | 5 |
| WIV-MDA/H1N2 | WIV | H1N2-δ1(1:7) | 10 | 5 |
| No MDA/H1N1 | None | H1N1pdm09(2:6)b | 10 | 5 |
| WIV-MDA/H1N1 | WIV | H1N1pdm09(2:6) | 10 | 5 |
| Study 2 | ||||
| No MDA/NC | None | None | 9 | - |
| No MDA/H1N1 | None | H1N1pdm09(2:6) | 8 | 5 |
| WIV-MDA/H1N1 | WIV | H1N1pdm09(2:6) | 8 | 5 |
| EXP-MDA/H1N1 | Experimental infectiona | H1N1pdm09(2:6) | 8 | 5 |
| No MDA/H1N2 | None | H1N2-δ1(1:7) | 8 | 5 |
| WIV-MDA/H1N2 | WIV | H1N2-δ1(1:7) | 8 | 5 |
| EXP-MDA/H1N2 | Experimental infectionc | H1N2-δ1(1:7) | 8 | 5 |
| NAT-MDA/H1N2 | Natural infectionc | H1N2-δ1(1:7) | 8 | - |
| Study 3 | ||||
| No MDA/WIV | None | WIV | 2 | - |
| WIV-MDA/WIV | WIV | WIV | 7 | - |
| No MDA/COM | None | Commercial | 2 | - |
| WIV-MDA/COM | WIV | Commercial | 7 | - |
a
Challenge strains for Studies 1&2, vaccine type for Study 3.
b
H1N2-δ1(1:7) = virus containing HA from A/swine/Minnesota/02011/08 H1N2 δ1 and the other seven genes from A/turkey/Ohio/313053/04 H3N2; H1N1pdm09(2:6)= virus containing the surface genes from A/California/04/2009 H1N1 and the other six genes from A/turkey/Ohio/313053/04 H3N2.
c
EXP-MDA pigs suckled sows which were previously naturally exposed and then experimentally boosted with live exposure to H1N1pdm09 and NAT-MDA pigs suckled sows which were previously naturally exposed to H1N1pdm09 only.